Evolus price target raised to $23 from $20 at Mizuho

Mizuho raised the firm’s price target on Evolus to $23 from $20 and keeps a Buy rating on the shares following the Q4 report. The firm now include sales estimates for Estyme and has greater confidence in Evolysse’s competitive profile given data from the Europe head-to-head trial.